Project Grant R01MH138401

Award Date 12/18/24
Completion Date 11/30/28
Dollars Obligated $729K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) will support a study on the impact of early-life psychostimulant exposure on sleep neurophysiology and circadian rhythms in an animal model of ADHD. The $181,234 grant will fund two main studies: 1) investigating the effects of methylphenidate on sleep architecture and neurophysiological activity in preadolescent and adult rodent...
The National Institute of Mental Health (NIMH) awarded a $857,216 Project Grant (CFDA 93.242 - Mental Health Research Grants) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, for a longitudinal study titled "Longitudinal EEG and Environmental Trajectories Leading to ADHD and Disruptive Behaviors from Infancy to Preschool". The 5-year study, starting December 1, 2024, aims to characterize the neurodevelopmental trajectories leading to early...
This federal Project Grant award from the National Institute of Mental Health's Mental Health Research Grants program (CFDA 93.242) in the amount of $2,535,618 will fund a study to advance the understanding of the genetic underpinnings of primary attention-deficit/hyperactivity disorder (ADHD). The key objectives are to: 1) develop the largest family-based repository of children with primary ADHD and their family members using consistent diagnostic criteria, 2) identify novel candidate genes...
The federal Project Grant award of $877,297.00 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, will support a study to map the mental health emergency response system (MHERS) across the United States. The key products and services to be delivered through this award include: Constructing a longitudinal, nationally-representative inventory of each state's MHERS resources, including the capacity and distribution of acute...
This $1,555,898 Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 - Mental Health Research Grants will fund a 5-year prospective cohort study examining the impact of structural and interpersonal racism on suicidal thoughts and behaviors (STB) among 320 Black children aged 6-11 years with Attention-Deficit/Hyperactivity Disorder (ADHD). The study aims to: 1) quantitatively assess how structural and interpersonal racism influence the development of STB in...
The National Institute of Mental Health (NIMH) awarded a $826,902 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. to examine the dynamic relationships between physical activity, sleep, and circadian rhythmicity with neurobehavioral heterogeneity in attention-deficit/hyperactivity disorder (ADHD). The 5-year grant, awarded on May 1, 2025 and running through April 30, 2030, will leverage wearable technology to...
This $180,896 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research at Pennsylvania State University's Milton S. Hershey Medical Center to develop a clinical decision support system (CDSS) to assess the risk and benefit of stimulant therapy for adults. The project aims to apply machine learning techniques to analyze integrated clinical and geosocial data to identify personalized risk factors...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $489,314 to Neurotrainer, Inc. from September 1, 2024 to February 28, 2026. The funding supports a feasibility and efficacy study of a virtual reality (VR) cognitive training intervention called Neurotrainer. The study aims to evaluate the efficacy of Neurotrainer in improving attentional and executive control functions, reducing inattention...
The National Institute of Mental Health (NIMH) awarded a Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The Children's Hospital of Philadelphia (CHOP) in the amount of $239,144 with a start date of August 6, 2024 and an end date of June 30, 2027. The purpose of this grant is to develop and pilot test caregiver-facing implementation strategies (called Supporting School Success for Caregivers or SSS-C) to support caregivers of children with or at-risk for...
This $367,708 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research on the neural underpinnings of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). The University of Southern California (USC) will use cutting-edge functional MRI techniques and advanced machine learning methods to investigate how connectivity patterns in the brain's reward circuitry differ...

This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $729,367 to The RAND Corporation to study the impacts of a prescription stimulant shortage on youth with Attention-Deficit Hyperactivity Disorder (ADHD). Specifically, the project will:

  1. Construct community-level measures of stimulant medication shortages and assess their relationship with demographic, socioeconomic, and healthcare characteristics.

  2. Evaluate whether youth in communities affected by the stimulant shortage experienced differential trends in ADHD, mental health, and substance use disorder treatment.

  3. Investigate treatment process, mental health, substance use, and educational consequences for ADHD patients whose treatment was interrupted by the shortage.

  4. Determine if there were disparate impacts based on patient race/ethnicity, urbanicity, prescriber specialty, and school/community characteristics.

The project aims to provide rigorous evidence on the health and non-health impacts of prescription drug shortages on vulnerable populations, which can inform regulators on mitigating the effects of supply disruptions. The award period runs from December 2024 through November 2028.

Generated 4/8/25, 4:07 AM